Biomarkers provide insight into the interactions between a cancer indication and the therapeutic at a molecular level. These insights empower decision making, and can be the difference between success and failure in the clinical setting.
Discovery’s experts help researchers adopt clinical trial ready immunohistochemistry (IHC) assays early in the drug development process as a low-cost, high-impact strategy to help accelerate clinical trials and improve clinical outcomes.
Luminos® is how Discovery Life Sciences enters the clinical genomics market, with a platform built on validated science, regulatory confidence, and the speed the oncology market demands
